Merck (MSD outside the U.S.)

Merck & Co., known as MSD outside the United States and Canada, is a global biopharmaceutical company headquartered in Rahway, New Jersey. The company markets medicines and vaccines across oncology, vaccines, hospital acute care, and other areas. Merck's regulatory filings and FDA product records document a portfolio anchored by immuno-oncology, human papillomavirus vaccination, and hospital anti-infectives.

Oncology is a defining franchise for Merck, led by pembrolizumab (Keytruda), an anti-PD-1 antibody with multiple FDA-approved indications documented in Drugs@FDA. The vaccines franchise includes Gardasil/Gardasil 9 for HPV prevention. Hospital acute care includes products such as bridion and prevymis, per FDA labeling. Merck also maintains cardiovascular, virology, and immunology programs described in SEC filings and trial registries.

• Keytruda label expansions continue to appear in FDA approval records and company regulatory announcements.
• Investor presentations filed with the SEC emphasize lifecycle management and combination studies for pembrolizumab.
• Merck pursues external innovation through collaborations and acquisitions disclosed in SEC 8-K filings.
• ClinicalTrials.gov lists ongoing Merck-sponsored studies across solid tumors and hematologic malignancies.

Merck's pipeline activity is traceable through SEC 10-K pipeline summaries, FDA approval letters, and ClinicalTrials.gov entries. Business development includes partnerships in oncology combinations and earlier-stage assets. For current trial phase, enrollment status, and regulatory milestones, consult primary filings rather than aggregated commentary.